These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 32736938

  • 1. HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination.
    Cornall AM, Saville M, Pyman J, Callegari ET, Tan FH, Brotherton JML, Malloy MJ, Tabrizi SN, Wrede CD, Garland SM, VACCINE Study Group.
    Vaccine; 2020 Sep 11; 38(40):6304-6311. PubMed ID: 32736938
    [Abstract] [Full Text] [Related]

  • 2. How best to interpret mixed human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia lesions.
    Callegari ET, Tabrizi SN, Pyman J, Saville M, Cornall AM, Brotherton JM, Garland SM.
    Vaccine; 2014 Jul 07; 32(32):4082-8. PubMed ID: 24857693
    [Abstract] [Full Text] [Related]

  • 3. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M, Xu L, Simoens C, Martin-Hirsch PP.
    Cochrane Database Syst Rev; 2018 May 09; 5(5):CD009069. PubMed ID: 29740819
    [Abstract] [Full Text] [Related]

  • 4. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G, HPV PATRICIA Study Group.
    Lancet Oncol; 2012 Jan 09; 13(1):89-99. PubMed ID: 22075171
    [Abstract] [Full Text] [Related]

  • 5. Assessment of attribution algorithms for resolving CIN3-related HPV genotype prevalence in mixed-genotype biopsy specimens using laser capture microdissection as the reference standard.
    Cornall AM, Brotherton JML, Callegari ET, Tan FH, Saville M, Pyman J, Phillips S, Malloy MJ, Tabrizi SN, Garland SM, VACCINE study group.
    Vaccine; 2020 Sep 11; 38(40):6312-6319. PubMed ID: 32736939
    [Abstract] [Full Text] [Related]

  • 6. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.
    Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Harjula K, Kuortti M, Natunen K, Palmroth J, Petäjä T, Pukkala E, Siitari-Mattila M, Struyf F, Nieminen P, Paavonen J, Dubin G, Dillner J.
    BMJ Open; 2017 Aug 18; 7(8):e015867. PubMed ID: 28821519
    [Abstract] [Full Text] [Related]

  • 7. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
    Perez S, Iñarrea A, Pérez-Tanoira R, Gil M, López-Díez E, Valenzuela O, Porto M, Alberte-Lista L, Peteiro-Cancelo MA, Treinta A, Carballo R, Reboredo MC, Alvarez-Argüelles ME, Purriños MJ.
    Virol J; 2017 Nov 06; 14(1):214. PubMed ID: 29110680
    [Abstract] [Full Text] [Related]

  • 8. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
    Song F, Yan P, Huang X, Wang C, Du H, Qu X, Wu R.
    BMC Cancer; 2022 Jan 06; 22(1):42. PubMed ID: 34991494
    [Abstract] [Full Text] [Related]

  • 9. Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.
    Brotherton JML, Tabrizi SN, Phillips S, Pyman J, Cornall AM, Lambie N, Anderson L, Cummings M, Payton D, Scurry JP, Newman M, Sharma R, Saville M, Garland SM.
    Int J Cancer; 2017 Oct 15; 141(8):1576-1584. PubMed ID: 28677147
    [Abstract] [Full Text] [Related]

  • 10. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
    Egli-Gany D, Spaar Zographos A, Diebold J, Masserey Spicher V, Frey Tirri B, Heusser R, Dillner J, Petignat P, Sahli R, Low N, CIN3+plus study group.
    BMC Cancer; 2019 Jan 30; 19(1):111. PubMed ID: 30700274
    [Abstract] [Full Text] [Related]

  • 11. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Cleveland AA, Gargano JW, Park IU, Griffin MR, Niccolai LM, Powell M, Bennett NM, Saadeh K, Pemmaraju M, Higgins K, Ehlers S, Scahill M, Johnson Jones ML, Querec T, Markowitz LE, Unger ER, HPV-IMPACT Working Group.
    Int J Cancer; 2020 Feb 01; 146(3):810-818. PubMed ID: 30980692
    [Abstract] [Full Text] [Related]

  • 12. Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact.
    Pérez-Castro S, Lorenzo-Mahía Y, Iñarrea Fernández A, Lamas-González MJ, Sarán-Díez MT, Rubio-Alarcón J, Reboredo-Reboredo MC, Mosteiro-Lobato S, López-Miragaya I, Torres-Piñón J, Melón-García S.
    Enferm Infecc Microbiol Clin; 2014 Oct 01; 32(8):479-85. PubMed ID: 24274937
    [Abstract] [Full Text] [Related]

  • 13. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.
    Simonella LM, Lewis H, Smith M, Neal H, Bromhead C, Canfell K.
    BMC Infect Dis; 2013 Mar 03; 13():114. PubMed ID: 23452957
    [Abstract] [Full Text] [Related]

  • 14. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial.
    Monsonego J, Cox JT, Behrens C, Sandri M, Franco EL, Yap PS, Huh W.
    Gynecol Oncol; 2015 Apr 03; 137(1):47-54. PubMed ID: 25667973
    [Abstract] [Full Text] [Related]

  • 15. High prevalence of HPV16 and high-grade cytology in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2.
    Damgaard RK, Jenkins D, Stoler MH, van de Sandt MM, Lycke KD, de Koning MNC, Quint WGV, Steiniche T, Petersen LK, Hammer A.
    Acta Obstet Gynecol Scand; 2023 Sep 03; 102(9):1227-1235. PubMed ID: 37469102
    [Abstract] [Full Text] [Related]

  • 16. Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study.
    Velentzis LS, Sitas F, O'Connell DL, Darlington-Brown J, Egger S, Sinha R, Banks E, Frazer IH, Canfell K.
    BMC Infect Dis; 2014 Dec 21; 14():3861. PubMed ID: 25528152
    [Abstract] [Full Text] [Related]

  • 17. HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix.
    Quint KD, de Koning MN, van Doorn LJ, Quint WG, Pirog EC.
    Gynecol Oncol; 2010 May 21; 117(2):297-301. PubMed ID: 20207397
    [Abstract] [Full Text] [Related]

  • 18. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.
    Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Miller D, Monsonego J, Munoz N, Myers E, Paavonen J, Pitisuttithum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.
    Cancer Epidemiol Biomarkers Prev; 2014 Oct 21; 23(10):1997-2008. PubMed ID: 25274978
    [Abstract] [Full Text] [Related]

  • 19. Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.
    Leeman A, Ebisch RMF, Kasius A, Bosgraaf RP, Jenkins D, van de Sandt MM, de Strooper LMA, Heideman DAM, Snijders PJF, Massuger LFAG, Bekkers RLM, Meijer CJLM, van Kemenade FJ, Quint WGV, Melchers WJG.
    Gynecol Oncol; 2018 Nov 21; 151(2):311-318. PubMed ID: 30219239
    [Abstract] [Full Text] [Related]

  • 20. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
    Osborne SL, Tabrizi SN, Brotherton JM, Cornall AM, Wark JD, Wrede CD, Jayasinghe Y, Gertig DM, Pitts MK, Garland SM, VACCINE Study group.
    Vaccine; 2015 Jan 01; 33(1):201-8. PubMed ID: 25444787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.